[go: up one dir, main page]

WO1996040170A3 - Metal-containing compounds and their use for inhibiting the immune response - Google Patents

Metal-containing compounds and their use for inhibiting the immune response Download PDF

Info

Publication number
WO1996040170A3
WO1996040170A3 PCT/US1996/005942 US9605942W WO9640170A3 WO 1996040170 A3 WO1996040170 A3 WO 1996040170A3 US 9605942 W US9605942 W US 9605942W WO 9640170 A3 WO9640170 A3 WO 9640170A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
immune response
inhibiting
metal
containing compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/005942
Other languages
French (fr)
Other versions
WO1996040170A2 (en
Inventor
Cecilia M Bastos
Timothy D Ocain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procept Inc
Original Assignee
Procept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procept Inc filed Critical Procept Inc
Publication of WO1996040170A2 publication Critical patent/WO1996040170A2/en
Publication of WO1996040170A3 publication Critical patent/WO1996040170A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of compounds as immunosuppressive agents to prevent or significantly reduce graft rejection in organ and bone marrow transplantation is described. The compounds described herein can also be used as immunosuppressant drugs for T-lymphocyte mediated autoimmune diseases, such as diabetes, and may be useful in alleviating psoriasis and contact dermatitis. The compounds can also be used therapeutically in the treatment of hyperproliferative vascular disease and to reduce/suppress the immune response in a mammal undergoing gene therapy.
PCT/US1996/005942 1995-06-07 1996-04-29 Metal-containing compounds and their use for inhibiting the immune response Ceased WO1996040170A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47934195A 1995-06-07 1995-06-07
US47295295A 1995-06-07 1995-06-07
US08/472,952 1995-06-07
US08/479,341 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040170A2 WO1996040170A2 (en) 1996-12-19
WO1996040170A3 true WO1996040170A3 (en) 1997-02-13

Family

ID=27043972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005942 Ceased WO1996040170A2 (en) 1995-06-07 1996-04-29 Metal-containing compounds and their use for inhibiting the immune response

Country Status (1)

Country Link
WO (1) WO1996040170A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711800A1 (en) * 1997-03-21 1998-09-24 Hoechst Ag Extension of expression of transgenic proteins by immunomodulating treatment
EP1391221A1 (en) * 2002-08-23 2004-02-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438756A1 (en) * 1990-01-04 1991-07-31 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Combination of cytostatic and cytotoxic active agents for use in therapeutic procedures
US5512687A (en) * 1994-10-28 1996-04-30 Procept, Inc. Compounds for inhibiting immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438756A1 (en) * 1990-01-04 1991-07-31 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Combination of cytostatic and cytotoxic active agents for use in therapeutic procedures
US5512687A (en) * 1994-10-28 1996-04-30 Procept, Inc. Compounds for inhibiting immune response

Also Published As

Publication number Publication date
WO1996040170A2 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
Mochizuki et al. A clinical trial of FK506 in refractory uveitis
Washton et al. Clonidine for opiate detoxification: outpatient clinical trials.
CA2229282A1 (en) Use of hyaluronic acid as an immunosuppressant
WO1992021313A3 (en) Novel immunosuppressive compounds
CA2238098A1 (en) Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis
AU1032888A (en) Thermophilic microbial treatment of precious metal ores
EP1438966A3 (en) Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.
CA2276606A1 (en) Method of treating prostatic diseases using active vitamin d analogues
HUT68332A (en) Novel immunsupressive compds. and pharmaceutical compns. contg. them
Duner et al. Histamine and leukocytes in blood during muscular work in man
KR910700055A (en) S-adenosyl-methionine for the treatment of immune rejection in pancreatitis and pancreas transplantation
MY105942A (en) Cyclosporin derivatives.
CA2006658A1 (en) An anticoagulant substance obtained from urine
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
AU6314296A (en) Therapeutic agents and autoimmune diseases
WO1996040170A3 (en) Metal-containing compounds and their use for inhibiting the immune response
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
HUP9802834A3 (en) Preparations for the treatment of t cell mediated autoimmune diseases
CA2385312A1 (en) Compositions and methods for preventing and treating transplant rejection
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
Thrower et al. Thymopoietin in rheumatoid arthritis
AU6062294A (en) Treatment of gold bearing ore
IL108926A0 (en) Human t cell monoclone, process for its production and its use for the treatment and diagnosis of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
AU6366994A (en) Methods for diagnosis and treatment of xscid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA